Phathom Pharmaceuticals, Inc. Company profile
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![](https://img.capital.com/imgs/articles/384x2000x0/meta_1.jpeg)
![](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0-infy.jpeg)
![](https://img.capital.com/imgs/articles/384x2000x0/tesla_0.jpeg)